Vinorelbine-Induced Phlebitis Is Common In Patients Receiving Adjuvant Chemotherapy For Non-Small Cell Lung Cancer (Nsclc).

e20016Background: The combination of vinorelbine and cisplatin is a highly established and widely used regimen as a standard of care for adjuvant therapy for NSCLC, as demonstrated in the JBR.10 and ANITA randomized trials. Vinorelbine is a moderate vesicant, and the incidence of vinorelbine-induced phlebitis (VIP) has been reported to be ~10-30%. However, previous trials involving vinorelbine/cisplatin as adjuvant therapy in NSCLC have not specifically reported on VIP. We evaluated the prevalence of VIP in resected NSCLC pts at our institution and assessed the impact of VIP on consequent treatment delays and/or alterations in planned adjuvant therapy. Methods: Pharmacy records were obtained for all pts who received vinorelbine at our institution from 1/2005-11/2015. Chart review was conducted on pts with a diagnosis of NSCLC and treated in our academic faculty clinics with vinorelbine. Charts were retrospectively reviewed for documentation of phlebitis occurrences, need for central catheter placement and...